Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results

Metabolic cardioprotection is an important part of treating patients with coronary heart disease (CHD). The most widely used drug in this group is trimetazidine. Its mechanism of action is based on fatty acids metabolism inhibition, glucose oxidation activation, intracellular ATP deficit prevention....

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	L. V. Kremneva, O. V. Abaturova, S. V. Shalaev
Formatua:	Artigo
Hizkuntza:	Russo
Argitaratua:	«SILICEA-POLIGRAF» LLC 2005-04-01
Saila:	Кардиоваскулярная терапия и профилактика
Gaiak:	metabolic cardioprotection trimetazidine stable angina myocardial infarction heart failure myocardial revascularization
Sarrera elektronikoa:	https://cardiovascular.elpub.ru/jour/article/view/938
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!